
Commentary|Podcasts|January 16, 2026
Pharma Pulse: Trump’s New Healthcare Roadmap, FDA Vaccine Warnings, and BPD to Lead The Agency Network
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, President Trump unveils a patient payment plan, the FDA flags a rare seizure risk for several leading flu vaccines, and MJH Life Sciences expands its data-driven reach.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- First, President Trump has unveiled "
The Great Healthcare Plan ," a proposal aimed at slashing prescription costs and maximizing price transparency. The plan seeks to bypass traditional insurance middlemen by allowing the government to pay funds directly into patient health savings accounts. - On the regulatory front, the FDA has
notified manufacturers of six different flu vaccines—including Sanofi and GSK—to add a new warning to their labels. Data from the last two seasons shows a small but increased risk of febrile seizures in children aged six months to four years on the day following vaccination. - Lastly, BPD Healthcare, a leading health brand strategy and communications firm,
announced it will lead The Agency Network, MJH Life Sciences’ pharmaceutical and biotech-focused agency. The integration brings together TAN’s pharmaceutical and biotech commercialization expertise with BPD Healthcare’s experience across health systems, providers and communities, creating a more comprehensive strategic partner for healthcare and life sciences brands.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
2
How GLP-1 Growth and Specialty Drugs Are Driving Cost Pressure
3
Why Packaging Is Now a Frontline Issue In Pharma Supply Chains
4
Report: GLP-1s, Oncology to Drive Drug Spending Surge in 2027
5




